胰腺癌：病理生物学、治疗选择和药物传递。
Pancreatic cancer: pathobiology, treatment options, and drug delivery.
机构信息
College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA.
出版信息
AAPS J. 2010 Jun;12(2):223-32. doi: 10.1208/s12248-010-9181-5. Epub 2010 Mar 3.
Abstract
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the USA. The high mortality rate is partly due to lack of effective treatments. This review summarizes the pathobiology and current treatment options for pancreatic cancer. Moreover, the review discusses the opportunities of developing novel therapies for pancreatic cancer provided by the progress in understanding the genetic mutations, tumor microenvironment, cancer stem cells, and drug delivery.
摘要
胰腺癌是美国癌症相关死亡的第四大主要原因。高死亡率部分归因于缺乏有效的治疗方法。本文综述了胰腺癌的病理生物学和当前治疗选择。此外，还讨论了通过对遗传突变、肿瘤微环境、癌症干细胞和药物输送的理解进展为胰腺癌开发新疗法提供的机会。
相似文献
1
Pancreatic cancer: pathobiology, treatment options, and drug delivery.胰腺癌：病理生物学、治疗选择和药物传递。
AAPS J. 2010 Jun;12(2):223-32. doi: 10.1208/s12248-010-9181-5. Epub 2010 Mar 3.
2
Pathobiology of pancreatic cancer: implications on therapy.胰腺癌的病理生物学：对治疗的影响
Expert Rev Anticancer Ther. 2016;16(2):219-27. doi: 10.1586/14737140.2016.1129276. Epub 2016 Jan 11.
3
Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.胰腺癌治疗的分子靶点：临床与实验研究
World J Gastroenterol. 2016 Jan 14;22(2):776-89. doi: 10.3748/wjg.v22.i2.776.
4
Stem cell-directed therapies in pancreatic cancer.胰腺癌中的干细胞定向治疗。
Curr Probl Cancer. 2013 Sep-Oct;37(5):280-6. doi: 10.1016/j.currproblcancer.2013.10.005. Epub 2013 Oct 8.
5
Targeted drug delivery in pancreatic cancer.胰腺癌中的靶向药物递送
Biochim Biophys Acta. 2010 Jan;1805(1):97-104. doi: 10.1016/j.bbcan.2009.10.001. Epub 2009 Oct 22.
6
Overcoming drug resistance in pancreatic cancer.克服胰腺癌的耐药性。
Expert Opin Ther Targets. 2011 Jul;15(7):817-28. doi: 10.1517/14728222.2011.566216. Epub 2011 Mar 11.
7
Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications.胰腺癌干细胞：肿瘤发生机制的新认识及其临床意义。
Langenbecks Arch Surg. 2010 Jan;395(1):1-10. doi: 10.1007/s00423-009-0502-z. Epub 2009 May 7.
8
Pancreatic Neoplasms and Autophagy.胰腺肿瘤与自噬。
Curr Drug Targets. 2018;19(9):1018-1023. doi: 10.2174/1389450117666160622220915.
9
The treatment of advanced pancreatic cancer: current evidence and future challenges.晚期胰腺癌的治疗：当前证据与未来挑战。
Ann Oncol. 2008 Sep;19 Suppl 7:vii304-8. doi: 10.1093/annonc/mdn461.
10
Emerging drugs in the treatment of pancreatic cancer.胰腺癌治疗中的新兴药物。
Expert Opin Emerg Drugs. 2009 Jun;14(2):311-28. doi: 10.1517/14728210902972502.
引用本文的文献
1
thermal-responsive hydrogels for combined photothermal therapy and chemotherapy of pancreatic cancer.用于胰腺癌光热疗法和化疗联合治疗的热响应水凝胶
RSC Adv. 2025 Apr 24;15(17):13119-13126. doi: 10.1039/d5ra00371g. eCollection 2025 Apr 22.
2
Novel mRNA biomarker-based liquid biopsy for the detection of resectable pancreatic cancer.基于新型mRNA生物标志物的液体活检用于可切除胰腺癌的检测。
BMC Cancer. 2025 Apr 23;25(1):762. doi: 10.1186/s12885-025-14124-w.
3
Designing live bacterial therapeutics for cancer.设计用于癌症治疗的活细菌疗法。
Adv Drug Deliv Rev. 2025 Jun;221:115579. doi: 10.1016/j.addr.2025.115579. Epub 2025 Apr 12.
4
Novel insight and perspectives of nanoparticle-mediated gene delivery and immune-modulating therapies for pancreatic cancer.纳米颗粒介导的胰腺癌基因递送与免疫调节疗法的新见解与展望
J Nanobiotechnology. 2024 Dec 19;22(1):771. doi: 10.1186/s12951-024-02975-7.
5
Intra-tumoral administration of CHST15 siRNA remodels tumor microenvironment and augments tumor-infiltrating T cells in pancreatic cancer.在胰腺癌中，瘤内注射CHST15小干扰RNA可重塑肿瘤微环境并增强肿瘤浸润性T细胞。
Mol Ther Oncol. 2024 May 3;32(2):200812. doi: 10.1016/j.omton.2024.200812. eCollection 2024 Jun 20.
6
Regional intra-arterial vs. systemic chemotherapy for the treatment of advanced pancreatic cancer: a systematic review and meta-analysis.区域动脉内化疗与全身化疗治疗晚期胰腺癌的系统评价和荟萃分析
Front Oncol. 2024 Apr 8;14:1197424. doi: 10.3389/fonc.2024.1197424. eCollection 2024.
7
Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems.基于纳米的药物递送系统在胰腺癌治疗中的进展
Pharmaceutics. 2023 Sep 21;15(9):2363. doi: 10.3390/pharmaceutics15092363.
8
BRD9-SMAD2/3 Orchestrates Stemness and Tumorigenesis in Pancreatic Ductal Adenocarcinoma.BRD9 通过调控 SMAD2/3 信号通路维持胰腺导管腺癌干细胞干性和肿瘤发生。
Gastroenterology. 2024 Jan;166(1):139-154. doi: 10.1053/j.gastro.2023.09.021. Epub 2023 Sep 21.
9
Tissue metabolomics identified new biomarkers for the diagnosis and prognosis prediction of pancreatic cancer.组织代谢组学鉴定出了用于胰腺癌诊断和预后预测的新生物标志物。
Front Oncol. 2022 Sep 2;12:991051. doi: 10.3389/fonc.2022.991051. eCollection 2022.
10
Chrysin-Induced G Protein-Coupled Estrogen Receptor Activation Suppresses Pancreatic Cancer.白杨素诱导的 G 蛋白偶联雌激素受体激活抑制胰腺癌。
Int J Mol Sci. 2022 Aug 26;23(17):9673. doi: 10.3390/ijms23179673.
本文引用的文献
1
2
Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.E2100的独立评估：一项贝伐单抗联合紫杉醇对比紫杉醇治疗转移性乳腺癌女性患者的III期试验
J Clin Oncol. 2009 Oct 20;27(30):4966-72. doi: 10.1200/JCO.2008.21.6630. Epub 2009 Aug 31.
3
Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.贝伐单抗联合氟尿嘧啶持续静脉滴注、亚叶酸钙和伊立替康（FOLFIRI）用于一线转移性结直肠癌的IV期研究。
Oncology. 2009;77(2):113-9. doi: 10.1159/000229787. Epub 2009 Jul 23.
4
Cancer. Breaching the cancer fortress.癌症。突破癌症堡垒。
Science. 2009 Jun 12;324(5933):1400-1. doi: 10.1126/science.1175940.
5
Emerging drugs in the treatment of pancreatic cancer.胰腺癌治疗中的新兴药物。
Expert Opin Emerg Drugs. 2009 Jun;14(2):311-28. doi: 10.1517/14728210902972502.
6
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.在胰腺癌小鼠模型中，抑制刺猬信号通路可增强化疗药物的递送。
Science. 2009 Jun 12;324(5933):1457-61. doi: 10.1126/science.1171362. Epub 2009 May 21.
7
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.西妥昔单抗联合化疗治疗晚期非小细胞肺癌患者（FLEX）：一项开放标签的随机III期试验。
Lancet. 2009 May 2;373(9674):1525-31. doi: 10.1016/S0140-6736(09)60569-9.
8
Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review.局部晚期胰腺癌治疗中的放化疗：一项定性系统评价
J Clin Oncol. 2009 May 1;27(13):2269-77. doi: 10.1200/JCO.2008.19.7921. Epub 2009 Mar 23.
9
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.贝伐单抗联合吉西他滨和厄洛替尼治疗转移性胰腺癌的III期试验。
J Clin Oncol. 2009 May 1;27(13):2231-7. doi: 10.1200/JCO.2008.20.0238. Epub 2009 Mar 23.
10
Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer.细胞间黏附分子（ICAM）-1或ICAM-2的表达在决定胰腺癌细胞对人γδ-T细胞介导的细胞溶解的敏感性方面至关重要：对基于γδ-T细胞的胰腺癌免疫疗法设计的启示。
J Gastroenterol Hepatol. 2009 May;24(5):900-11. doi: 10.1111/j.1440-1746.2008.05668.x. Epub 2008 Nov 3.
Zotero 插件